Developer docs
API playgroundTry for free, no card

Search company profiles

Complex Disorders Alliance

Full company profile

uuid022q75n

Namestring
Complex Disorders Alliance
Legal namestring
Complex Disorders Alliance
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit research organization headquartered in Stamford, Connecticut, that funds and coordinates neuroimmune research on complex chronic disorders including Long COVID, ME/CFS, POTS, EDS/HSD, MCAS, chronic migraine, and endometriosis. Founded in 2024 by Fidji Simo (CEO of Instacart, diagnosed with POTS in 2019) and led by CEO Amy Rochlin, CODA operates across five interconnected neuroimmune research domains: neuroimmune signaling, immune network dysregulation, viral and microbial persistence, CSF/glymphatics/cerebral blood flow, and structural mechanics/instability.

CODA's technical core is an AI-driven multi-omics analytics and patient sub-typing platform that integrates genetic data, immune profiling, clinical questionnaires, and wearable data to identify computable phenotypes and biologically informed patient subgroups. The organization builds proprietary value through research programs (MetX registry and biorepository, MELO genomic study, CODA CCD Initiative, Microvascular and Endothelial Research Initiative, Sequence ME & Long COVID whole-genome program), clinical trials (Anktiva, Inspiritol, Vagus Nerve Modulation), and the Solve Together patient data platform managed under its Brain Inflammation Collaborative partnership. AI and combinatorial analytics are primarily delivered through partnerships with PrecisionLife, ChronicleBio, CareEvolution, and academic medical centers including MIT, Stanford, Johns Hopkins, Brown, Edinburgh, Stellenbosch, and Nova Southeastern.

CODA does not sell products or services. Its revenue model is philanthropic: voluntary donations (processed via GiveButter), grants from partner foundations such as the Metrodora Foundation, and co-funding for government-backed research programs (e.g., £4.75M UK government funding for Sequence ME & Long COVID). Customers are not commercial buyers but rather three stakeholder groups: patients participating in registries and trials, researchers and clinicians using the data platform, and research foundations and disease organizations collaborating within the alliance. The organization operates on a community-led, non-commercial go-to-market model focused on building the richest longitudinal dataset for complex disorders to de-risk downstream biotech and pharma investment.

Short descriptiontext

Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit that funds and coordinates AI-driven neuroimmune research across Long COVID, ME/CFS, POTS, and related complex chronic disorders, serving patients, researchers, clinicians, and disease foundations through collaborative studies, registries, and clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStamford, United States
HQ citystring
Stamford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nonprofit medical research, neuroimmune research, patient registry biorepository, multi-omics analytics, chronic disease research
Industry3 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
SECONDARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
NAICS code1 code
  • Other Similar Organizations (except Business, Professional, Labor, and Political Organizations)813990
SIC code2 codes
  • Services-Health Services8000
  • Services-Misc Health & Allied Services, Nec8090
Product category
Nonprofit Medical Research
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Philanthropic Donations
TypeGrants Donations
Description

CODA accepts charitable donations from individuals, foundations, and organizations to fund neuroimmune research programs. Donations are voluntary and non-refundable, processed through secure third-party payment platforms.

complexdisorders.org
2Research Grants and Foundation Funding
TypeGrants Donations
Description

CODA receives funding from partner foundations and research grants to support specific studies and clinical initiatives, including collaborations with Metrodora Foundation and other institutional partners.

complexdisorders.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 4 records shown
1CODA CCD (Craniocervical Dysfunction Initiative)
Description

Research initiative investigating how altered neuroimmune signaling at the craniocervical junction contributes to complex chronic disorders

complexdisorders.org
+3 more records
Core offering1 text field

Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit that funds, coordinates, and accelerates neuroimmune research for complex chronic disorders including Long COVID, ME/CFS, POTS, EDS/HSD, MCAS, chronic migraine, and endometriosis. The organization operates integrated research programs, patient registries, biorepositories, and clinical studies through alliances with academic centers, disease foundations, and biotech partners, applying AI-driven multi-omics analytics for patient subtyping and therapeutic development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 88% of long COVID genetic risk factors identified in UK cohort successfully replicated in US All of Us dataset across diverse ancestries
+2 more records
Product overview1 text field

CODA (Complex Disorders Alliance) is a 501(c)(3) nonprofit patient-founded research organization that operates as a patient-driven research ecosystem focused on accelerating neuroimmune research for complex chronic disorders. Rather than a traditional product company, CODA functions as a research accelerator providing multiple integrated research programs, clinical studies, and initiatives. The portfolio includes: CODA CCD Initiative (craniocervical dysfunction research), the MELO Study (genetic subtyping collaboration with PrecisionLife), MetX Study (patient registry and biorepository at Metrodora Institute), multiple clinical trials (Anktiva, Inspiritol, Vagus Nerve Modulation), the Sequence ME & Long COVID genomic program, and the CODA Fellowships. CODA Sub-Typing serves as the AI-driven analytical framework across all programs. CODA also participates in the Solve Together platform (managed by Brain Inflammation Collaborative). All programs focus on five interconnected neuroimmune research domains: neuroimmune signaling, immune network dysregulation, viral and microbial persistence, CSF/glymphatics/cerebral blood flow, and structural mechanics/instability.

Product and service9 records
1CODA CCD (Craniocervical Dysfunction) Initiative
CategoryResearch Program
Description

A landmark research initiative investigating how altered neuroimmune signaling at the craniocervical junction contributes to initiation and progression of complex chronic disorders; encompasses the Modified Delphi Process, Sub-Typing Initiative, Glymphatics Study, and Multi-Center Tissue Study for researchers and patient communities.

2MELO Study
CategoryResearch Study
Description

A collaborative study combining patient-reported data and genomic analysis to identify risk factors and disease subtypes for ME/CFS and Long COVID, pairing ChronicleBio clinical infrastructure with PrecisionLife AI-driven disease modeling to determine biological subtypes and predictive genetic risk patterns.

3MetX Study
CategoryResearch Study
Description

A landmark study at Metrodora Institute that established a patient registry, biorepository, and core infrastructure to support future multi-omics research in complex disorders.

4Sequence ME & Long COVID
CategoryResearch Program
Description

The world's largest long-read, whole-genome sequencing study analyzing complete genetic code of 9,000 people with ME and 9,000 people with Long COVID to identify rare and structural genetic changes underlying these conditions; CODA participates as a funding partner.

5CODA Microvascular and Endothelial Research Initiative
CategoryResearch Program
Description

Translational research program focused on venous and microvascular blood flow problems, inflammation, and reduced oxygen delivery in complex neuroimmune disorders including Long COVID and ME/CFS, led by Professor Resia Pretorius at Stellenbosch University.

6Anktiva Open Label Mechanistic Study
CategoryClinical Trial
Description

Open label study evaluating Anktiva (IL-15 superagonist immunotherapy) in patients with complex neuroimmune disorders, investigating immune mechanisms, biologic response, and clinical signals while building a characterized longitudinal patient dataset and biorepository.

7Inspiritol Phase I/2b Clinical Trial
CategoryClinical Trial
Description

Phase 1/2b randomized clinical trial evaluating Inspiritol, a proprietary nebulized immunomodulatory therapy, in ME/CFS and Long COVID patients, assessing safety, biologic response, and early clinical efficacy with longitudinal immune profiling.

8CODA Fellowships
CategoryFellowship Program
Description

Fellowship programs supporting researchers working across neuroimmune research domains to advance subtyping, integrate data, and connect biological insight to therapeutic strategy.

9Solve Together Patient Database Platform
CategoryData Platform
Description

Dynamic patient database platform created by CareEvolution allowing users to track symptoms, sync wearables, generate reports for providers, and opt into clinical studies; the largest database of its kind in the U.S. for ME/CFS and related conditions, managed by Brain Inflammation Collaborative.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Stellenbosch University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Professor Resia Pretorius at Stellenbosch University leads CODA-supported microvascular research investigating fibrinaloid microclots, hyperactivated platelets, and inflammation-endothelial injury cycles in Long COVID and ME/CFS.

complexdisorders.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Dr. Mikki Tal at MIT leads the MAESTRO study and collaborates with Stellenbosch University on microvascular research. MIT research focuses on shared immune mechanisms across conditions, sex-based differences in immune response, and predictive diagnostics for complex chronic disorders.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-29
Description

Solve M.E. is a national nonprofit dedicated to ME/CFS, Long Covid, and IACCIs. CODA partners with Solve M.E. to share patient data, accelerate research, and drive faster diagnoses and treatments. Solve M.E.'s Solve Together patient database platform is being managed by Brain Inflammation Collaborative with data shared with CODA and ChronicleBio.

4Brain Inflammation Collaborative (BIC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-29
Description

BIC is a patient-centered nonprofit taking over management of the Solve Together platform from Solve M.E., expanding it to include pediatric populations and additional diagnoses. BIC will help illuminate links between brain inflammation and mental health, with materials translated into Spanish.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-29
Description

ChronicleBio is a biotech company building an AI-ready data platform for chronic illness. They receive Solve M.E.'s patient data to fuel clinical trials and build the world's most comprehensive longitudinal dataset for ME/CFS, Long COVID, and related conditions.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-04-29
Description

CareEvolution is a health data and digital clinical research platform provider with 15+ years of healthcare interoperability experience. They created the Solve Together platform that enables symptom tracking, wearable syncing, and clinical study enrollment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-28
Description

PrecisionLife provides combinatorial analytics platform for genetic analysis of Long COVID and ME/CFS. Their AI-driven technology identified and reproduced genetic risk factors across US and UK populations with diverse ancestries, supporting drug repurposing and diagnostic development.

8Metrodora Foundation / Metrodora Institute
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-28
Description

Metrodora Foundation funds flagship clinical programs (MetX and MELO studies) at Metrodora Institute. CODA collaborates on the MELO Study to identify biomarkers in ME/CFS and Long COVID, combining patient data with PrecisionLife's genetic analysis for precision diagnostics and drug discovery.

complexdisorders.org
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Action for ME leads the Sequence ME & Long COVID study in partnership with the University of Edinburgh and Oxford Nanopore Technologies. Multiple organizations including CODA, Solve ME/CFS, and Schmidt Initiative for Long COVID co-funded initial phase, catalyzing £4.75M in UK government funding.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Dr. Nancy Klimas at Nova Southeastern University serves as Principal Investigator for the Anktiva open label mechanistic study evaluating IL-15 superagonist immunotherapy in patients with complex neuroimmune disorders.

11University of Edinburgh
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

University of Edinburgh partners with Action for ME and Oxford Nanopore Technologies on Sequence ME & Long COVID, the world's largest long-read whole-genome sequencing study analyzing genetic code of 18,000 participants.

complexdisorders.org
Strategic tierSupportingTypeTechnology or Integration
Description

Oxford Nanopore Technologies provides long-read whole-genome sequencing technology for Sequence ME & Long COVID study, enabling analysis of rare and structural genetic changes in ME/CFS and Long COVID patients.

13The Multiple Myeloma Research Foundation (MMRF)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

MMRF serves as a research model reference for CODA. MMRF transformed cancer research by building collaborative tissue banks, sequencing first cancer genome, and launching nearly 100 trials, helping approve over 15 new drugs.

complexdisorders.org
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Solve ME/CFS Initiative is a nonprofit partner that jointly supported the initial phase of Sequence ME & Long COVID research, contributing to the £4.75M UK government funding for genome sequencing of ME/CFS and Long COVID patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight12 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based ME charity leading the Sequence ME & Long COVID whole-genome sequencing study alongside University of Edinburgh and Oxford Nanopore — a direct partner/peer of CODA in the same genomics program and broader ME research ecosystem.

TypeDirect peer
Description

Nonprofit supporting Long COVID and ME/CFS research with a focus on persistent infection, microvascular pathology, and immune dysfunction — overlapping directly with CODA's microvascular and viral persistence research domains.

TypeBroad incumbent
Description

Mature disease-specific nonprofit explicitly cited by CODA as the operating model for its research accelerator strategy; operates tissue banks, sequencing programs, and nearly 100 trials that helped approve 15+ drugs — the gold-standard analog for what CODA aspires to build in neuroimmune disorders.

TypeDirect peer
Description

Nonprofit that funds and coordinates multi-site ME/CFS and Long COVID research with a focus on collaborative science, biomarker discovery, and clinical translation — closely aligned with CODA's cross-condition research accelerator approach.

TypeDirect peer
Description

Clinical care and research center specializing in ME/CFS, Long COVID, and related complex disorders, running patient registries, clinician training, and clinical trials that overlap directly with CODA's research domains.

TypeDirect peer
Description

Major philanthropic initiative funding Long COVID research and co-funder of the Sequence ME & Long COVID program — a direct funding peer to CODA in the same disease space.

7Metrodora Foundation
TypeDirect peer
Description

Foundation funding the MetX patient registry/biorepository and MELO biomarker study at Metrodora Institute in collaboration with CODA and PrecisionLife — a direct peer/partner operating in the same neuroimmune research stack.

8Brain Inflammation Collaborative
TypeDirect peer
Description

Patient-centered nonprofit focused on brain inflammation in complex chronic illness that now manages the Solve Together data platform under the multi-party alliance with CODA and Solve M.E.

9Pandemic Patients
TypeDirect peer
Description

Patient advocacy and research nonprofit focused on Long COVID and post-infection chronic illness — closely comparable to CODA in patient-led research mobilization and coalition building.

TypeDirect peer
Description

Long-standing national nonprofit dedicated to ME/CFS and Long COVID that operates disease-specific research programs, the Solve Together patient registry, and advocacy — a near-perfect direct peer to CODA in both mission and operating model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Complex Disorders Alliance

Nonprofit Medical Researchcomplexdisorders.org

Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit that funds and coordinates AI-driven neuroimmune research across Long COVID, ME/CFS, POTS, and related complex chronic disorders, serving patients, researchers, clinicians, and disease foundations through collaborative studies, registries, and clinical trials.

What Complex Disorders Alliance does

Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit research organization headquartered in Stamford, Connecticut, that funds and coordinates neuroimmune research on complex chronic disorders including Long COVID, ME/CFS, POTS, EDS/HSD, MCAS, chronic migraine, and endometriosis. Founded in 2024 by Fidji Simo (CEO of Instacart, diagnosed with POTS in 2019) and led by CEO Amy Rochlin, CODA operates across five interconnected neuroimmune research domains: neuroimmune signaling, immune network dysregulation, viral and microbial persistence, CSF/glymphatics/cerebral blood flow, and structural mechanics/instability.

CODA's technical core is an AI-driven multi-omics analytics and patient sub-typing platform that integrates genetic data, immune profiling, clinical questionnaires, and wearable data to identify computable phenotypes and biologically informed patient subgroups. The organization builds proprietary value through research programs (MetX registry and biorepository, MELO genomic study, CODA CCD Initiative, Microvascular and Endothelial Research Initiative, Sequence ME & Long COVID whole-genome program), clinical trials (Anktiva, Inspiritol, Vagus Nerve Modulation), and the Solve Together patient data platform managed under its Brain Inflammation Collaborative partnership. AI and combinatorial analytics are primarily delivered through partnerships with PrecisionLife, ChronicleBio, CareEvolution, and academic medical centers including MIT, Stanford, Johns Hopkins, Brown, Edinburgh, Stellenbosch, and Nova Southeastern.

CODA does not sell products or services. Its revenue model is philanthropic: voluntary donations (processed via GiveButter), grants from partner foundations such as the Metrodora Foundation, and co-funding for government-backed research programs (e.g., £4.75M UK government funding for Sequence ME & Long COVID). Customers are not commercial buyers but rather three stakeholder groups: patients participating in registries and trials, researchers and clinicians using the data platform, and research foundations and disease organizations collaborating within the alliance. The organization operates on a community-led, non-commercial go-to-market model focused on building the richest longitudinal dataset for complex disorders to de-risk downstream biotech and pharma investment.

Complex Disorders Alliance firmographics

Firmographics
Name
Complex Disorders Alliance
Legal name
Complex Disorders Alliance
Website
https://complexdisorders.org
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit that funds and coordinates AI-driven neuroimmune research across Long COVID, ME/CFS, POTS, and related complex chronic disorders, serving patients, researchers, clinicians, and disease foundations through collaborative studies, registries, and clinical trials.
Ownership category
akta.pro rank

Complex Disorders Alliance industry classification

Industry
Product category
Nonprofit Medical Research
NAICS
Other Similar Organizations (except Business, Professional, Labor, and Political Organizations) (813990)
SIC
Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
SECONDARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)

Keywords

  • Nonprofit medical research
  • Neuroimmune research
  • Patient registry biorepository
  • Multi-omics analytics
  • Chronic disease research

Where Complex Disorders Alliance is headquartered

Location

Headquarters

HQ city
Stamford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Complex Disorders Alliance business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Philanthropic Donations: CODA accepts charitable donations from individuals, foundations, and organizations to fund neuroimmune research programs. Donations are voluntary and non-refundable, processed through secure third-party payment platforms.
  2. Research Grants and Foundation Funding: CODA receives funding from partner foundations and research grants to support specific studies and clinical initiatives, including collaborations with Metrodora Foundation and other institutional partners.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Complex Disorders Alliance product offering

Product offering

Core offering

Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit that funds, coordinates, and accelerates neuroimmune research for complex chronic disorders including Long COVID, ME/CFS, POTS, EDS/HSD, MCAS, chronic migraine, and endometriosis. The organization operates integrated research programs, patient registries, biorepositories, and clinical studies through alliances with academic centers, disease foundations, and biotech partners, applying AI-driven multi-omics analytics for patient subtyping and therapeutic development.

Product overview

CODA (Complex Disorders Alliance) is a 501(c)(3) nonprofit patient-founded research organization that operates as a patient-driven research ecosystem focused on accelerating neuroimmune research for complex chronic disorders. Rather than a traditional product company, CODA functions as a research accelerator providing multiple integrated research programs, clinical studies, and initiatives. The portfolio includes: CODA CCD Initiative (craniocervical dysfunction research), the MELO Study (genetic subtyping collaboration with PrecisionLife), MetX Study (patient registry and biorepository at Metrodora Institute), multiple clinical trials (Anktiva, Inspiritol, Vagus Nerve Modulation), the Sequence ME & Long COVID genomic program, and the CODA Fellowships. CODA Sub-Typing serves as the AI-driven analytical framework across all programs. CODA also participates in the Solve Together platform (managed by Brain Inflammation Collaborative). All programs focus on five interconnected neuroimmune research domains: neuroimmune signaling, immune network dysregulation, viral and microbial persistence, CSF/glymphatics/cerebral blood flow, and structural mechanics/instability.

Differentiator

Problem solved

Functional benefit

Brands

  • CODA CCD (Craniocervical Dysfunction Initiative): Research initiative investigating how altered neuroimmune signaling at the craniocervical junction contributes to complex chronic disorders
  • CODA Microvascular and Endothelial Research Initiative
  • MetX Study
  • MELO Study

Products and services

  • CODA CCD (Craniocervical Dysfunction) Initiative A landmark research initiative investigating how altered neuroimmune signaling at the craniocervical junction contributes to initiation and progression of complex chronic disorders; encompasses the Modified Delphi Process, Sub-Typing Initiative, Glymphatics Study, and Multi-Center Tissue Study for researchers and patient communities.
  • MELO Study A collaborative study combining patient-reported data and genomic analysis to identify risk factors and disease subtypes for ME/CFS and Long COVID, pairing ChronicleBio clinical infrastructure with PrecisionLife AI-driven disease modeling to determine biological subtypes and predictive genetic risk patterns.
  • MetX Study A landmark study at Metrodora Institute that established a patient registry, biorepository, and core infrastructure to support future multi-omics research in complex disorders.
  • Sequence ME & Long COVID The world's largest long-read, whole-genome sequencing study analyzing complete genetic code of 9,000 people with ME and 9,000 people with Long COVID to identify rare and structural genetic changes underlying these conditions; CODA participates as a funding partner.
  • CODA Microvascular and Endothelial Research Initiative Translational research program focused on venous and microvascular blood flow problems, inflammation, and reduced oxygen delivery in complex neuroimmune disorders including Long COVID and ME/CFS, led by Professor Resia Pretorius at Stellenbosch University.
  • Anktiva Open Label Mechanistic Study Open label study evaluating Anktiva (IL-15 superagonist immunotherapy) in patients with complex neuroimmune disorders, investigating immune mechanisms, biologic response, and clinical signals while building a characterized longitudinal patient dataset and biorepository.
  • Inspiritol Phase I/2b Clinical Trial Phase 1/2b randomized clinical trial evaluating Inspiritol, a proprietary nebulized immunomodulatory therapy, in ME/CFS and Long COVID patients, assessing safety, biologic response, and early clinical efficacy with longitudinal immune profiling.
  • CODA Fellowships Fellowship programs supporting researchers working across neuroimmune research domains to advance subtyping, integrate data, and connect biological insight to therapeutic strategy.
  • Solve Together Patient Database Platform Dynamic patient database platform created by CareEvolution allowing users to track symptoms, sync wearables, generate reports for providers, and opt into clinical studies; the largest database of its kind in the U.S. for ME/CFS and related conditions, managed by Brain Inflammation Collaborative.

Quantifiable outcome

  • 88% of long COVID genetic risk factors identified in UK cohort successfully replicated in US All of Us dataset across diverse ancestries
  • +2 more outcomes

Companies that use Complex Disorders Alliance

Customer profile

Segments3 records

Ideal customer profiles3 records

Complex Disorders Alliance technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Complex Disorders Alliance partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and supporting.

  • Stellenbosch UniversitycoreStrategic or Co-development Partner · 13 May 2026Professor Resia Pretorius at Stellenbosch University leads CODA-supported microvascular research investigating fibrinaloid microclots, hyperactivated platelets, and inflammation-endothelial injury cycles in Long COVID and ME/CFS.
  • Massachusetts Institute of Technology (MIT)coreStrategic or Co-development Partner · 13 May 2026Dr. Mikki Tal at MIT leads the MAESTRO study and collaborates with Stellenbosch University on microvascular research. MIT research focuses on shared immune mechanisms across conditions, sex-based differences in immune response, and predictive diagnostics for complex chronic disorders.
  • Solve M.E.coreStrategic or Co-development Partner · 29 April 2025Solve M.E. is a national nonprofit dedicated to ME/CFS, Long Covid, and IACCIs. CODA partners with Solve M.E. to share patient data, accelerate research, and drive faster diagnoses and treatments. Solve M.E.'s Solve Together patient database platform is being managed by Brain Inflammation Collaborative with data shared with CODA and ChronicleBio.
  • Brain Inflammation Collaborative (BIC)coreStrategic or Co-development Partner · 29 April 2025BIC is a patient-centered nonprofit taking over management of the Solve Together platform from Solve M.E., expanding it to include pediatric populations and additional diagnoses. BIC will help illuminate links between brain inflammation and mental health, with materials translated into Spanish.
  • ChronicleBiocoreStrategic or Co-development Partner · 29 April 2025ChronicleBio is a biotech company building an AI-ready data platform for chronic illness. They receive Solve M.E.'s patient data to fuel clinical trials and build the world's most comprehensive longitudinal dataset for ME/CFS, Long COVID, and related conditions.
  • CareEvolutionsupportingTechnology or Integration · 29 April 2025CareEvolution is a health data and digital clinical research platform provider with 15+ years of healthcare interoperability experience. They created the Solve Together platform that enables symptom tracking, wearable syncing, and clinical study enrollment.
  • PrecisionLifecoreStrategic or Co-development Partner · 28 February 2025PrecisionLife provides combinatorial analytics platform for genetic analysis of Long COVID and ME/CFS. Their AI-driven technology identified and reproduced genetic risk factors across US and UK populations with diverse ancestries, supporting drug repurposing and diagnostic development.
  • Metrodora Foundation / Metrodora InstitutecoreStrategic or Co-development Partner · 28 February 2025Metrodora Foundation funds flagship clinical programs (MetX and MELO studies) at Metrodora Institute. CODA collaborates on the MELO Study to identify biomarkers in ME/CFS and Long COVID, combining patient data with PrecisionLife's genetic analysis for precision diagnostics and drug discovery.
  • Action for MEsupportingStrategic or Co-development PartnerAction for ME leads the Sequence ME & Long COVID study in partnership with the University of Edinburgh and Oxford Nanopore Technologies. Multiple organizations including CODA, Solve ME/CFS, and Schmidt Initiative for Long COVID co-funded initial phase, catalyzing £4.75M in UK government funding.
  • Nova Southeastern UniversitysupportingStrategic or Co-development PartnerDr. Nancy Klimas at Nova Southeastern University serves as Principal Investigator for the Anktiva open label mechanistic study evaluating IL-15 superagonist immunotherapy in patients with complex neuroimmune disorders.
  • University of EdinburghsupportingStrategic or Co-development PartnerUniversity of Edinburgh partners with Action for ME and Oxford Nanopore Technologies on Sequence ME & Long COVID, the world's largest long-read whole-genome sequencing study analyzing genetic code of 18,000 participants.
  • Oxford Nanopore TechnologiessupportingTechnology or IntegrationOxford Nanopore Technologies provides long-read whole-genome sequencing technology for Sequence ME & Long COVID study, enabling analysis of rare and structural genetic changes in ME/CFS and Long COVID patients.
  • The Multiple Myeloma Research Foundation (MMRF)supportingStrategic or Co-development PartnerMMRF serves as a research model reference for CODA. MMRF transformed cancer research by building collaborative tissue banks, sequencing first cancer genome, and launching nearly 100 trials, helping approve over 15 new drugs.
  • Solve ME/CFS InitiativesupportingStrategic or Co-development PartnerSolve ME/CFS Initiative is a nonprofit partner that jointly supported the initial phase of Sequence ME & Long COVID research, contributing to the £4.75M UK government funding for genome sequencing of ME/CFS and Long COVID patients.

Scale indicators10 records

Recent moves6 records

Expansion highlights12 records

Complex Disorders Alliance competitors and assessment

Company assessment

Direct peers

  • Action for ME: UK-based ME charity leading the Sequence ME & Long COVID whole-genome sequencing study alongside University of Edinburgh and Oxford Nanopore — a direct partner/peer of CODA in the same genomics program and broader ME research ecosystem.
  • PolyBio Research Foundation: Nonprofit supporting Long COVID and ME/CFS research with a focus on persistent infection, microvascular pathology, and immune dysfunction — overlapping directly with CODA's microvascular and viral persistence research domains.
  • Open Medicine Foundation: Nonprofit that funds and coordinates multi-site ME/CFS and Long COVID research with a focus on collaborative science, biomarker discovery, and clinical translation — closely aligned with CODA's cross-condition research accelerator approach.
  • Bateman Horne Center: Clinical care and research center specializing in ME/CFS, Long COVID, and related complex disorders, running patient registries, clinician training, and clinical trials that overlap directly with CODA's research domains.
  • Schmidt Initiative for Long COVID: Major philanthropic initiative funding Long COVID research and co-funder of the Sequence ME & Long COVID program — a direct funding peer to CODA in the same disease space.
  • Metrodora Foundation: Foundation funding the MetX patient registry/biorepository and MELO biomarker study at Metrodora Institute in collaboration with CODA and PrecisionLife — a direct peer/partner operating in the same neuroimmune research stack.
  • Brain Inflammation Collaborative: Patient-centered nonprofit focused on brain inflammation in complex chronic illness that now manages the Solve Together data platform under the multi-party alliance with CODA and Solve M.E.
  • Pandemic Patients: Patient advocacy and research nonprofit focused on Long COVID and post-infection chronic illness — closely comparable to CODA in patient-led research mobilization and coalition building.
  • Solve M.E. (Solve ME/CFS Initiative): Long-standing national nonprofit dedicated to ME/CFS and Long COVID that operates disease-specific research programs, the Solve Together patient registry, and advocacy — a near-perfect direct peer to CODA in both mission and operating model.

Broad incumbents

  • Multiple Myeloma Research Foundation: Mature disease-specific nonprofit explicitly cited by CODA as the operating model for its research accelerator strategy; operates tissue banks, sequencing programs, and nearly 100 trials that helped approve 15+ drugs — the gold-standard analog for what CODA aspires to build in neuroimmune disorders.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Complex Disorders Alliance social profiles

Digital presence

Complex Disorders Alliance financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Complex Disorders Alliance leadership team

Management profile

Number of profiles

Profiles5 records

Complex Disorders Alliance funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Complex Disorders Alliance M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Complex Disorders Alliance

What does Complex Disorders Alliance do?

Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit that funds, coordinates, and accelerates neuroimmune research for complex chronic disorders including Long COVID, ME/CFS, POTS, EDS/HSD, MCAS, chronic migraine, and endometriosis. The organization operates integrated research programs, patient registries, biorepositories, and clinical studies through alliances with academic centers, disease foundations, and biotech partners, applying AI-driven multi-omics analytics for patient subtyping and therapeutic development.

Is Complex Disorders Alliance a public or private company?

Complex Disorders Alliance is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Complex Disorders Alliance founded?

Complex Disorders Alliance was founded in 2024. It employs 1 to 10 people.

Where is Complex Disorders Alliance based?

Complex Disorders Alliance is headquartered in Stamford, United States, in the North America region.

How does Complex Disorders Alliance make money?

Two revenue lines are on record. Philanthropic Donations are the primary driver. The others are research Grants and Foundation Funding.

Who are Complex Disorders Alliance's main competitors?

Direct peers on record are Action for ME, PolyBio Research Foundation, Open Medicine Foundation, Bateman Horne Center, Schmidt Initiative for Long COVID, Metrodora Foundation, Brain Inflammation Collaborative, Pandemic Patients and Solve M.E. (Solve ME/CFS Initiative). Multiple Myeloma Research Foundation is listed as a broad incumbent.

Does Complex Disorders Alliance have an API?

No public API is recorded for Complex Disorders Alliance.

What industry is Complex Disorders Alliance in?

Complex Disorders Alliance's product category is Nonprofit Medical Research. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 813990 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals